Table 1.
The pharmacogenetics of certain genes associated with the pathophysiology or efficacy, metabolism, or availability of pharmacotherapeutic agents in mood disorders.
| Site of Action | Gene | Promoter Region | Anomaly |
|---|---|---|---|
| Serotonin transporter | SLC6A4 | 5-HTTPLR | SSRI-efficacy |
| P-Glycoprotein | ABCB1 | Upstream/downstream promoters | ABC-transporter1 |
| CRH-receptor of HPA axis2 | CRHR1 | Luciferase reporter plasmid | Suicidality |
| 5-HT2A receptor | HTR2A | −1438G/A (rs6311) | Overdensity |
| Glucocorticoid receptor | NR3C1 | Luciferase reporter plasmid | Stress adaptation |
| BDNF3 neurotrophin | BDNF | Multiple promoters | AD-enhanced plasticity |
| AD-drug action |
MAGI2, DTWD1. WDFY4, and CHL1 |
Multiple promoters | Symptom-exacerbation |
1
Transportation of a wide variety of substrates across extra- and intracellular membranes
2
Corticotrophin-releasing hormone (CRH) of the hypothalamic-pituitary-adrenal axis (HPA)
3
Brain derived neurotrophic factor (BDNF)